2-[(11E,13E)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-15-[(4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl)oxymethyl]-16-ethyl-4-hydroxy-5,9,13-trimethyl-2,10-dioxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-[(11E,13E)-6-[5-(4,5-dihydroxy-4,6-dimethyloxan-2-yl)oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-15-[(4,5-dihydroxy-3-methoxy-6-methyloxan-2-yl)oxymethyl]-16-ethyl-4-hydroxy-5,9,13-trimethyl-2,10-dioxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
• 化学式: C₄₅H₇₅NO₁₇
• 分子量: 902.1
• InChiKey: UFUYRGNJTFAODM-LWEGYUNWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  63
• 可旋转键数：
  12
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.84
• 拓扑面积：
  250
• 氢给体数：
  6
• 氢受体数：
  18

文献信息

• Macrolide solid-state forms
  申请人：Intervet International BV

  公开号：EP2019112A1

  公开（公告）日：2009-01-28

  This invention relates to solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms.

  本发明涉及20,23-二哌啶基-5-O-链霉素基-泰龙环酮的溶剂化和非溶剂化晶体形式，以及制备这种晶体形式的方法，包含或来源于这种晶体形式的药物，制备包含或来源于这种晶体形式的药物的方法，使用这种晶体形式进行治疗的方法以及包含这种晶体形式的工具箱。
• 20,23-PIPERIDINYL-5-O-MYCAMINOSYL-TYLONOLIDE POLYMORPHS
  申请人：Intervet International B.V.

  公开号：EP3170833A1

  公开（公告）日：2017-05-24

  This invention relates to solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms.

  本发明涉及 20,23-二哌啶基-5-O-mycaminosyl-tylonolide 的溶解和非溶解结晶形式，以及制造这种结晶形式的方法、包含（或衍生自）这种结晶形式的药物、制造包含（或衍生自）这种结晶形式的药物的方法、使用这种结晶形式的治疗方法和包含这种结晶形式的试剂盒。
• MACROLIDE SOLID-STATE FORMS
  申请人：Intervet International B.V.

  公开号：EP2181117B1

  公开（公告）日：2016-11-09
• Macrolide Synthesis Process and Solid-State Forms
  申请人：Blatter Fritz

  公开号：US20090042815A1

  公开（公告）日：2009-02-12

  This invention relates to a method for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides. This invention also relates to solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms.
• MACROLIDE SYNTHESIS PROCESS AND SOLID-STATE FORMS
  申请人：Blatter Fritz

  公开号：US20120208779A1

  公开（公告）日：2012-08-16

  Described are methods for making macrolides, and, in particular, a method for making optionally substituted 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide and derivatives thereof, as well as uses of macrolides to make medicaments, methods of treatment using macrolides, and methods for making intermediates that, inter alia, may be used to make macrolides. Also described are solvated and non-solvated crystalline forms of 20,23-dipiperidinyl-5-O-mycaminosyl-tylonolide, as well as methods for making such crystalline forms, medicaments comprising (or derived from) such crystalline forms, methods for making medicaments comprising (or derived from) such crystalline forms, methods of treatment using such crystalline forms, and kits comprising such crystalline forms.